Global Dupuytren’s Disease Market

Global Dupuytren’s Disease Market, By Disease Type (Type I, Type II, and Type III), By Type (Diagnosis (Physical Examination, and X-ray) and Treatment (Surgery, Radiation Therapy, Needle Aponeurotomy, Steroid Shot, Enzyme Injection, Occupational Therapy, and Others), By End User (Hospitals, Clinics, Academic & Research Institute, and Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Dupuytren's disease is a condition that affects the palmar fascia - the fibrous layer of tissue that lies underneath the skin and above the tendons, nerves, blood vessels, and bones in the palm and fingers. In patients with Dupuytren's disease, the fascia thickens and contracts (shortens) over time. The fascia may pull on the fingers during this process, causing them to be forced inward, toward the palm. This may make it difficult or impossible to fully straighten the fingers, resulting in what is known as a "Dupuytren's contracture." In some people, a worsening Dupuytren's contracture can interfere with hand function, making it difficult to perform daily activities. When this occurs, there are non-surgical and surgical treatment options available to help slow the progression (worsening) of the disease and improve motion in the affected fingers. The cause of Dupuytren contracture is unknown. The condition tends to run in families. It is more common in men than in women. Dupuytren contracture gets worse slowly, over years. The condition begins with a firm lump in the palm of the hand. This lump can be painful or painless. Over time, the lump can extend into a hard cord under the skin and up into the finger. This cord tightens and pulls the finger toward the palm, sometimes severely.

Market Dynamics:

The increasing prevalence of Dupuytren's disease is expected to drive the growth of the global Dupuytren’s disease market over the forecast period. For instance, according to data published in October 2022 by Cision US Inc., a public relations and earned media software company and services provider, an estimated 14 million people are affected by Dupuytren's disease every year in North America.

Key features of the study:

• This report provides an in-depth analysis of the global Dupuytren’s disease market, and provides market size (US$ Bn ) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Dupuytren’s disease market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Endo International Plc, Bristol-Meyers Squibb Company, Spear Pharmaceuticals, GSK Plc., AstraZeneca, Hikma Pharmaceuticals Plc, LEO Pharma A/S, Fresenius Kabi AG, Bayer AG, Novartis AG, Pfizer Inc., Nantong Jinghua Pharmaceutical Co., Ltd., and Actiza Pharmaceutical Pvt. Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Dupuytren’s disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Dupuytren’s disease market

Detailed Segmentation:

• Global Dupuytren’s Disease Market Segmentation, By Disease Type:
• Type I
• Type II
• Type III
• Global Dupuytren’s Disease Market Segmentation, By Type:
• Diagnosis
• Physical Examination
• X-ray
• Treatment
• Surgery
• Radiation Therapy
• Needle Aponeurotomy
• Steroid Shot
• Enzyme Injection
• Occupational Therapy
• Others
• Global Dupuytren’s Disease Market Segmentation, By End User:
• Hospitals
• Clinics
• Academic & Research Institute
• Others
• Global Dupuytren’s Disease Market Segmentation, By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
• Company Profile:
• Endo International Plc
• Bristol-Meyers Squibb Company
• Spear Pharmaceuticals
• GSK Plc.
• AstraZeneca
• Hikma Pharmaceuticals Plc
• LEO Pharma A/S
• Fresenius Kabi AG
• Bayer AG
• Novartis AG
• Pfizer Inc.
• Nantong Jinghua Pharmaceutical Co., Ltd.
• Actiza Pharmaceutical Pvt. Ltd.